Links

Homepage

Stock List

Search by Ticker

News

Login

Spdr Series Trust Spdr S&p Bio (NYSEArca:XBI)
Stock Analysis

XBI113.92
▲ 4.2%4.59

Stock Analysis

The following stock analysis is based on 7.4 years of data (i.e. since Feb 25, 2013). All the stock history has been downloaded.

Stock Exchange

Spdr Series Trust Spdr S&p Bio trades on the NYSEArca exchange in USD dollars.

Sector

It is in the sector.

Current Status of Spdr Series Trust Spdr S&p Bio

It is currently trading at $113.92 ($109.33 the previous day).

Financials

The current Canada / US exchange rate is 1.3387.



Will This Trend Continue?

The year over year average increase is 5.3% per year assuming steady exponential growth. The actual 5 year average is 6.4. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year87.8035374149662.2- Below Average
2 year85.906048387097-3.4- Below Average
3 year88.89330543933131.2+ Above Average
4 year67.75640816326510.6+ Above Average
5 year61.273333333333-8.6- Below Average

Risk

The worst drop it has had in recent years is -49.4%. It has a shape to the stock curve, which means

Stock shape test

DAYS AG0PRICE
10114.92DROPPING
30113.67RISING
60103.49RISING
15089.18RISING
36585.68RISING
80092.21DROPPING
120068.81RISING
160051.31RISING
200065DROPPING


With an average increase of 5.3% year over year, if Spdr Series Trust Spdr S&p Bio is bought at the worst time, Stockmarketizer analysts estimate it will take 111.8 months before the stock will recover to the original purchase price.

Tradingview BuySell Widget

Yahoo News Feed

Biotech IPOs Capture Record $7.5 Billion in Second Quarter

Thu, 23 Jul 2020 20:42:25 The popularity of the sector continues with 57 new companies on tap to go public Continue reading...... Read Full Article

ETF Areas for July as Second Wave of Coronavirus Hits Hard

Tue, 30 Jun 2020 20:47:08 As the COVID-19 outbreak continues to aggravate in the United States, we discuss some ETF areas that investors can consider for investing in July.... Read Full Article

New Pharma ETF Focuses on Testing and Treatment for Infectious Diseases--but Not Covid-19

Sun, 28 Jun 2020 20:51:05 GERM offers investors exposure to established providers and ‘unsung heroes’ of biotech and life sciences Continue reading...... Read Full Article

Try These ETF Areas in Virus-Impacted Second Half of 2020

Wed, 24 Jun 2020 21:55:09 Here we highlight a few ETF areas that have the potential to do well in the second half of this year amid the coronavirus crisis.... Read Full Article

Biotech Stocks Are Getting Ready to Run. How to Play It.

Sat, 20 Jun 2020 13:48:00 Given the amount of attention paid to Covid-19 treatments and vaccines, it would be easy to assume that all of the good news was already reflected in biotech stocks. That’s not quite the case.... Read Full Article

Best ETF Ideas for the Second Half of 2020

Thu, 11 Jun 2020 20:07:08 We discuss how investors should position their portfolios for the new normal.... Read Full Article

Biotech Funds Testing Multi-Year Resistance

Tue, 09 Jun 2020 13:55:44 Biotech funds are testing their 2015 highs, setting the stage for a major breakout or painful reversal.... Read Full Article

These ETF Areas Make Great Investment Choices in June

Tue, 02 Jun 2020 20:55:08 Here we highlight some ETF areas that will make interesting investment options for investors amid the coronavirus crisis.... Read Full Article

Why virus stocks are driving market volatility

Mon, 01 Jun 2020 12:03:00 The market’s erratic response to lukewarm medical research for COVID-19 treatment and vaccine candidates isn’t expected to slow down as investors pin their hopes for an economic recovery on the high-risk biotechnology sector.... Read Full Article

Biotech ETFs Are Soaring. These Four Are Still Worth Considering.

Mon, 01 Jun 2020 12:00:00 Investors have been bullish on biotech, in the hope that companies will soon come up with a treatment, cure, or vaccine for Covid-19. But there’s more to biotech than the coronavirus, and even though these ETFs have risen, they ...... Read Full Article

Telehealth is going to and'become the defaultand' for patients: Ro CEO

Fri, 22 May 2020 11:46:27 Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.... Read Full Article

3 Charts That Suggest Biotech Stocks Are Headed Higher

Wed, 20 May 2020 17:30:14 Breakouts beyond key levels of resistance suggest that the bulls are in control of the momentum in the biotech sector.... Read Full Article

Moderna COVID-19 vaccine data is ‘baby-step’ in right direction: Expert

Mon, 18 May 2020 18:47:12 Professor of Medicine at Yale and Director of The Yale New Haven Hospital Center for Outcomes Research and Evaluation Dr. Harlan Krumholz joins Yahoo Finance’s Seana Smith to discuss Moderna’s recent headway in an early-stage coronavirus vaccine trial.... Read Full Article

Biotech ETFs trade higher on upbeat coronavirus results

Mon, 18 May 2020 14:51:00 Biotechnology-themed exchange-traded funds surged higher late Monday morning as investors rewarded pharmaceutical companies that looked likely to profit from treatments for COVID-19. The SPDR SandP Biotech ETF was up 3.1%, and the iShares NASDAQ Biotechnology ETF gained more than 2%. Two funds ...... Read Full Article

3 ETFs in Focus as Race for Vaccine Intensifies

Mon, 18 May 2020 14:03:51 Several companies sit at the forefront of developing a coronavirus vaccine. Gain exposure to each using the following three ETFs.... Read Full Article

What’s the most shorted sector? The answer might surprise you

Sat, 16 May 2020 17:34:00 Will markets go up or down as we move toward summer? No one knows for sure, but one metric to watch is activity among short sellers — investors who believe a particular security will decline in value.... Read Full Article

Cassava stock falls on failed Alzheimerand's study

Fri, 15 May 2020 15:31:00 Shares of Cassava Sciences Inc. tumbled 73.2% in trading on Friday after the company said its investigational Alzheimerand's disease treatment failed a mid-stage trial. The experimental drug, PTI-125, did not meet the primary endpoint (reducing cerebrospinal fluid (CSF) levels of tau ...... Read Full Article

ETF Short Sellers Are Targeting Retail, Biotech

Wed, 13 May 2020 16:31:02 The SandP 50o has come roaring back in the past two months, but there are still plenty of skeptics when it comes to the recent rally.There is currently $168.2 billion in aggregate domestic ETF short interest, according to S3 Partners ...... Read Full Article

Biotech Funds Could Rally to New Highs

Fri, 08 May 2020 15:05:11 Biotech funds have rallied within striking distance of multi-year resistance and could break out in coming weeks.... Read Full Article

Stocks surge as more states move to reopen amid coronavirus

Tue, 05 May 2020 19:11:46 JP Morgan Private Bank Head of Cross-Asset Thematic Strategy Anastasia Amoroso joins Yahoo Finance’s Seana Smith to discuss the latest market action as more states move to reopen their economies in the wake of the coronavirus. ... Read Full Article
<